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Introduction: Patients with rheumatoid arthritis (RA) are at an increased risk of malignancies compared with the
general population. This has raised concerns regarding these patients, particularly with the widespread use of
immunomodulating therapies, including biologic disease-modifying antirheumatic drugs (DMARDs). We performed
a systematic literature review and analysis to quantify the incidence of malignancies in patients with RA and the
general population to update previously published data.
Methods: A literature search was conducted that was consistent with and similar to that in a meta-analysis
published in 2008. MEDLINE, BIOSIS Previews, Embase, Derwent Drug File and SciSearch databases were searched
using specified search terms. Predefined inclusion criteria identified the relevant observational studies published
between 2008 and 2014 that provided estimates of relative risk of malignancy in patients with RA compared with
the general population. Risk data on overall malignancy and site-specific malignancies (lymphoma, melanoma and
lung, colorectal, breast, cervical and prostate cancer) were extracted. The standardized incidence ratios (SIRs; a
measure of risk) relative to the general population were evaluated and compared with published rates.
Results: A total of nine publications met the inclusion criteria. Seven of these reported SIRs for overall malignancy;
eight for lymphoma, melanoma, and lung, colorectal and breast cancer; seven for prostate cancer; and four for
cervical cancer. Compared with those in the general population, the SIR estimates for patients with RA suggest a
modest increased risk in overall malignancy, as previously observed. Patients with RA continued to show an increased
risk of lymphoma and lung cancer compared with the general population. Overall, SIR estimates for colorectal and
breast cancers continued to show a decrease in risk, whereas cervical cancer, prostate cancer and melanoma appeared
to show no consistent trend in risk among patients with RA compared with the general population.
Conclusions: The additional data evaluated here are consistent with previously reported data. Patients with RA are at
an increased risk of lung and lymphoma malignancies compared with the general population. Quantifying differences
in malignancy rates between non-biologic and biologic DMARD-treated patients with RA may further highlight which
malignancies may be related to treatment rather than to the underlying disease.Introduction
Rheumatoid arthritis (RA) is a polygenic, multifactorial
and chronic immune-mediated disease characterized by
chronic joint inflammation, a predilection for develop-
ment of joint damage and deformity, and extraarticular
involvement [1]. The management of RA includes the
use of biologic and non-biologic disease-modifying anti-
rheumatic drugs (DMARDs) [2, 3], which act by directly
modifying immunologic pathways involved in the patho-
genesis of RA. The risk of malignancy among patients* Correspondence: teresa.simon@bms.com
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cause of the autoimmune pathogenesis that underlies
RA, the common etiology between rheumatic disease
and malignancy, and the use of immunomodulatory
therapy, such as DMARDs, that may alter normal immu-
nosurveillance and elevate the risk of malignancy [4, 5].
Understanding this potential therapeutic risk has be-
come more relevant with the increasing use of biologic
DMARDs as a routine therapeutic approach to RA man-
agement [3]. With more biologic treatment options avail-
able and initiation of biologic treatments occurring earlier,
it is important to understand the baseline risk of malig-
nancies in patients with RA. Furthermore, continuouse is distributed under the terms of the Creative Commons Attribution 4.0
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literature are crucial to allow better understanding of the
background rates for malignancy in clinical trials and ob-
servational research evaluating real-world practice.
Smitten et al. [6] performed a meta-analysis on the
risk of overall malignancy and several site-specific can-
cers, including overall lymphoma, Hodgkin disease, non-
Hodgkin lymphoma, lung cancer, colorectal cancer and
breast cancer, using data published between 1990 and
2007. Their meta-analysis suggested a small overall in-
crease in risk of malignancy, which was elevated for
lymphoma, Hodgkin disease, non-Hodgkin lymphoma
and lung cancer, but they found a decreased risk of colo-
rectal and breast cancer in patients with RA compared
with the general population [6]. The malignancies in-
cluded were prespecified and based on the most fre-
quently reported malignancies in an RA population.
In this article, we review the data on the incidence of
malignancy reported since the Smitten et al. [6] meta-
analysis and additionally evaluate the risk of other im-
portant site-specific malignancies, namely, melanoma,
cervical cancer and prostate cancer, which have been a
topic of discussion in recent publications [7–9].
Methods
Literature search
We conducted a search of the MEDLINE, BIOSIS
Previews, Embase, Derwent Drug File and SciSearch
databases for literature published between 1 January 2008
and 30 November 2014, using the following specified
search terms: cancer or tumor, tumour, malign* and rheu-
matoid arthritis or RA, and epidemiolog* or inciden*,
population, observation, retrospective or occurren*.
Exclusion algorithm
Predefined inclusion criteria were used to identify rele-
vant observational studies that provided estimates of
relative risk of malignancy in patients with RA compared
with the general population. The same criteria as de-
tailed by Smitten et al. [6] were applied. Studies were eli-
gible for inclusion if they fulfilled the following criteria:
(1) observational study design (including prospective,
retrospective, epidemiologic, database, survey, registry,
cohort and case–control), (2) reported malignancy out-
comes in patients with RA and a general population, (3)
enrolled more than 100 patients, (4) included only
patients older than 18 years of age, (5) covered any
geographic region and (6) were reported in English as a
full-length publication. Citations meeting the inclusion
criteria were obtained and screened for the outcomes of
interest, which included the observed incidence rates of
total malignancy and lymphoma, lung, colorectal, breast,
melanoma, prostate and cervical cancers in patients with
RA compared with the expected incidence rates in thegeneral population. Lymphoma was reported as Hodgkin
or non-Hodgkin where available. The selection of studies
for inclusion was made without regard to evaluation of
specific RA management strategies. We attempted to
avoid overlap by excluding studies for which updated
publications were available. We also excluded studies
that compared specific RA biologic treatments with
other RA treatments, unless overall RA and general
population rates were reported.Data presentation
Citations meeting the inclusion criteria were screened for
outcomes of interest. Risk data on overall malignancy and
site-specific malignancies (overall lymphoma, Hodgkin
disease, non-Hodgkin lymphoma, melanoma, and lung,
colorectal, breast, cervical and prostate cancers) were
extracted independently by two people and compared for
accuracy. Study-specific estimates of relative risk were
measured mostly by overall and age- and sex-adjusted
standardized incidence ratios (SIRs) relative to non-RA
patients or the general population. In one study using a
case–control approach, researchers reported an odds
ratio, which is an accurate estimator of the relative risk
[10]. Thus, all measures of relative risk and their res-
pective 95 % confidence intervals (CIs) were then com-
pared with previously published rates. Pooled relative risks
and 95 % CIs were then computed using the DerSimonian
and Laird technique [11], in which a random-effects
model takes into consideration both within-study and
between-studies variation by incorporating the hetero-
geneity of the effects in the overall analysis. Some studies
in which authors reported data separately for colon and
rectal cancer, or for men and women, were considered
separate studies when we pooled relative risks.Results
A total of 136 articles were identified using the defined
search criteria (Fig. 1). Following identification, a total of
33 potential publications were further analyzed; of these, 9
studies met all the inclusion criteria (Fig. 1) [10, 12–19].
These studies included population- and community-based
RA cohorts, examined data from 458 to 84,475 patients
and had mean follow-up periods ranging from 4 to
25 years. The relative risk of overall malignancy was
reported in seven studies [12–15, 17–19]; lymphoma
(overall lymphoma, Hodgkin disease or non-Hodgkin
lymphoma), lung, colorectal and breast cancers and mel-
anoma in eight [10, 12–17, 19]; prostate cancer in seven
[10, 12–17]; and cervical cancer in four [12, 14, 16, 17].
Overall risk by malignancy type was reported in eight
studies [10, 12–17, 19], both overall risk and risk by sex
were reported in three [15, 17, 18] and risk stratified by










10 publications met inclusion criteria
(1 publication was previously cited in
Smitten et al. [6] as in press and 
therefore was not included)   
–8 non-English publications
–60 not full manuscript publications (i.e. meeting abstracts)
–28 not observational-type studies (i.e. reviews, meta-analyses, case reports)
–12 did not compare data to general population
–6 did not report malignancy outcomes
–4 did not report incidence data
–1 reported malignancy not evaluated in this publication
Fig. 1 Literature search data
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In general, SIRs for overall malignancy across the studies
were similar. Six of seven studies reported a significant in-
crease in overall risk of malignancy (Fig. 2) [12–15, 17–32].
The total pooled SIR (95 % CI) for studies analyzed by
Smitten et al. (1.05 [1.01–1.09]) [6] and those included
here was significant: 1.09 (1.06–1.13). With the addition of
the newer studies, there was no change in the overall sum-
mary statistic showing that patients with RA have a 10 %
increase in overall malignancy risk compared with the
general population.
Lymphoma
In eight studies, authors reported outcomes as either
overall lymphoma, Hodgkin disease or non-Hodgkin
lymphoma [10, 12–17, 19]. Two studies reported only
lymphoma, whereas the remaining six studies reported
overall lymphoma, Hodgkin disease and non-Hodgkin
lymphoma rates, with all of the new studies reporting a sig-
nificant increase in risk of lymphoma in patients with RA
compared with the general population (Figs. 3, 4 and 5).
This ranged from almost a doubling (SIR 1.75) (Fig. 3)
[10, 15, 17, 21, 23, 24, 29, 30, 33] to a 12-fold increase(SIR 12.82) (Fig. 4) [12, 14–16, 19, 22, 24, 25, 27–29, 34, 35]
in the risk of developing lymphoma. The pooled SIR for
Hodgkin disease (Fig. 4) was higher than for non-Hodgkin
lymphoma (Fig. 5) [12–16, 19, 20, 22, 24, 25, 27–29, 34–36].
The total pooled SIR (95 % CI) for the studies reviewed
here and by Smitten et al. [6] was 2.46 (2.05–2.96) for ma-
lignant lymphoma, 3.21 (2.42–4.27) for Hodgkin disease
and 2.26 (1.82–2.81) for non-Hodgkin lymphoma. The
overall risk with the addition of the new studies is con-
sistent with previously reported SIRs (2.08 [1.80–2.39],
3.29 [2.56–4.22] and 1.95 [1.70–2.24], respectively) [6];
however, a slight increase in risk for non-Hodgkin disease
was noted.
Lung cancer
In eight studies, authors reported that patients with RA
had an increased risk of lung cancer compared with the
general population [10, 12–17, 19]. The SIRs (95 % CI) for
lung cancer ranged from 1.36 (1.34–1.38) to 2.9 (1.6–4.8)
(Fig. 6) [10, 12–17, 19–22, 24–28, 32, 36–38]. The total
pooled SIR (95 % CI) for the studies reviewed here and by
Smitten et al. [6] was 1.64 (1.51–1.79) for lung cancer.
The risk of lung cancer in patients with RA compared
Source n/N SIR (95% CI)
Matteson 1991 (DMARDs) [32] 20/530 1.52 (0.90, 2.6)†
Gridley  1993 [24] 840/11,683 0.95 (0.9, 1.0)
Moritomo 1995 [26] 26/655 1.38 (0.90, 2.02)
Kauppi 1996 [31] 540/9469 1.16 (1.07, 1.26)
Mellemkjaer 1996 [25] 1832/20,699 1.08 (1.03, 1.13)§
Cibere1997 [22] 136/862 0.8 (0.67, 0.95)
Thomas 2000 [27] 2029/26,623 1.01 (1.0, 1.1)
Ekstrom 2003 [29] 8896/76,527 1.07 (1.05, 1.09)
Askling 2005 [21] 3379/53,067 1.05 (1.01, 1.08)
Askling 2005 (early RA) [21] 138/3703 1.1 (0.9, 1.3)‡
Askling 2005 (anti-TNF) [21] 67/4160 0.9 (0.7, 1.2)‡
Geborek 2005 [30] 69/800 1.4 (1.1, 1.8)‡
Geborek 2005 (anti-TNF) [30] 16/757 1.1 (0.6, 1.8)
Abasolo 2007 [20] 25/789 1.2 (0.8, 1.8)†
Franklin 2007 [23] 92/1237 1.1 (0.9, 1.3)†
Wolfe 2007 [28] 543/13,869 1.0 (1.0, 1.1)†
Buchbinder 2008 [19] 64/458 1.5 (1.2, 1.9)
Hemminki 2008 [14] 4366/42,262 1.23 (1.19, 1.27)
Chen 2011 [12] 935/23,644 1.12 (1.11, 1.13)
Yamada 2011 [17] 173/7566 1.18 (1.02, 1.37)
Female* 1.13 (0.94, 1.36)
Male* 1.29 (0.99, 1.67)
Kim 2012 [18] 30/1501 0.86 (0.58, 1.23)
Female* 0.99 (0.65, 1.42)
Male* 0.31 (0.04, 1.11)
Dreyer 2013 [13] 128/3812 1.25 (1.05, 1.48)
Mercer 2013 [15] 182/3771 1.28 (1.10, 1.48)
Female* 1.38 (1.15, 1.64)
Male* 1.11 (0.85, 1.44)
Total pooled SIR 23 1.09 (1.06, 1.13)
0.1 10.01.0
New studies
Fig. 2 Relative risk of overall malignancy in patients with rheumatoid arthritis (RA) compared with the general population. CI, confidence interval;
DMARD, disease-modifying antirheumatic drug; n, number of malignancies; N, population size; RR, relative risk; SIR, standardized incidence ratio;
TNF, tumor necrosis factor. *SIRs by sex are not included in the total pooled SIR. †Excluding non-melanoma skin cancer. ‡All solid tumors. §Excluding
lymphatic and hematopoietic
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is consistent with what was previously observed (1.63
[1.43–1.87]) [6].
Colorectal cancer
In seven studies [12, 14–17, 19], authors reported that
patients with RA had a decreased risk of colon or
colorectal cancer, with SIRs (95 % CI) ranging from
0.49 (0.26–0.83) to 0.96 (0.56–1.54) (Fig. 7) [10, 12–17,
19–22, 24–28, 31, 36]. However, in some studies, authors
reported SIRs >1, with the highest being 1.53 (0.69–3.42)Source n/N
Gridley 1993 [24] 48/11,683
Ekstrom 2003 [29] 535/76,527
Askling 2005 [21] 319/53,067
 Askling (early RA) [21] 11/3703
Askling 2005 (anti-TNF) [21] 9/4160
Geborek 2005 [30] 2/800
Geborek 2005 (anti-TNF) [30] 5/757
Franklin 2007 [23] 9/1237
Wolfe 2007 [33] 95/19,591
Hellgren 2010† [10] 19/6745
Yamada 2011 [17] 20/7566
Female*
Male*
Mercer 2013 [15] 21/3771
Female*
Male*
Total pooled SIR 12
0
New studies
Fig. 3 Relative risk of malignant lymphoma in patients with rheumatoid ar
interval; n, number of malignancies; N, population size; OR, odds ratio; SIR,
are not included in the total pooled SIR. †Reported as odds ratiofor rectal cancer [10, 13]. For colorectal cancer, the total
pooled SIR (95 % CI) for the studies reviewed by Smitten
et al. (0.77 [0.65–0.90]) [6] plus those included here was
0.78 (0.71–0.86).
Breast cancer
For breast cancer, there was generally no increase in
risk; estimated risk varied from 0.63 to 1.21 in the new
studies [10, 12–17, 19] (Fig. 8) [10, 12–17, 19–22,
24–28, 36]. The total pooled SIR (95 % CI) for the




















thritis (RA) compared with the general population. CI, confidence
standardized incidence ratio; TNF, tumor necrosis factor. *SIRs by sex
Parikh-Patel 2009 [16]
Source n/N SIR (95% CI)
Gridley 1993 [24] 12/11,683 2.34 (1.2, 4.1)
Mellemkjaer 1996 [25] 14/20,699 3.4 (1.8, 5.6)
Cibere 1997 [22] 0/862 0.0 (0.00, 8.53)
Kauppi 1997 [34] 4/9469 2.2 (0.6, 5.7)
Thomas 2000 [27] 17/26,623 3.85 (2.2, 6.2)
Mariette 2002 (MTX) [35] 7/30,000 7.4 (3.0, 15.3)
Ekstrom 2003 [29] 77/76,527 3.06 (2.42, 3.83)
Wolfe 2007 [28] 4/13,869 3.0 (1.3, 6.8)
Buchbinder 2008 [19] 1/458 8.9 (0.2, 49.8)
Hemminki 2008 [14] 35/42,262 4.05 (2.82, 5.63)
25/84,475
Female* 1.62 (0.91, 2.68)
Male* 2.76 (1.32, 5.08)
Chen 2011 [12] 1/23,644 1.76 (1.45, 2.17)
Mercer 2013 [15] 5/3771 12.82 (4.16, 29.92)
 Total pooled SIR 14 3.21 (2.42, 4.27)
0 50.01.0
New studies
Fig. 4 Relative risk of Hodgkin disease in patients with rheumatoid arthritis (RA) compared with the general population. CI, confidence interval;
n, number of malignancies; N, population size; MTX, methotrexate; SIR, standardized incidence ratio. *SIRs by sex for Parikh-Patel et al. [16] are included
in the total pooled SIR, as overall SIR was not available in their study
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for breast cancer.
Melanoma and cervical and prostate cancers
As previously noted, we included three additional malig-
nancies (melanoma and cervical and prostate cancer) in
our assessment that were not included in the Smitten
et al. meta-analysis [6]. Figs. 9, 10 and 11 highlight the ar-
ticles analyzed by Smitten et al. [6] and the newer studies
included in our assessment. For melanoma, we reviewed
17 studies (9 from Smitten et al. [20–22, 24–28, 36] and 8
new [10, 12–17, 19]). Of these, the overall range of SIRs
was 0.3–8.83, and five studies [12, 14, 19, 28, 36] showed a
significant increase in the risk of melanoma in the RA
population, ranging from 1.29 to 3.0 (Fig. 9) [10, 12–17,
19–22, 24–28, 36]. The total pooled SIR was 1.23 (1.01–
1.49).
For cervical cancer, SIRs were reported in a total of 13
studies (nine from Smitten et al. [20–22, 24–28, 36] andSource n/N
Gridley 1993 [24] 36/11,683
Mellemkjaer 1996 [25] 85/20,699
Cibere 1997 [22] 3/862
Kauppi 1997 [34] 34/9469
Mariette 2002 [35] 18/30,000
Thomas 2000 [27] 101/26,623
Ekstrom 2003 [29] 458/76,527
Setoguchi 2006 (DMARDs) [36] 58/7830
Abasolo 2007 [20] 3/789
Wolfe 2007 [28] 42/13,869
Buchbinder 2008 [19] 8/458
Hemminki 2008 [14] 280/42,262
Parikh-Patel 2009 [16] 325/84,475
Female*
Male*
Chen 2011 [12] 59/23,644
Dreyer 2013 [13] 5/3812
Mercer 2013 [15] 16/3771
Female*
Male*
Total pooled SIR     17
0.1
New studies
Fig. 5 Relative risk of non-Hodgkin lymphoma in patients with rheumatoid
interval; DMARD, disease-modifying antirheumatic drug; n, number of malig
sex included in total pooled SIR only if overall SIR was not availablefour new [12, 14, 16, 17]). Overall, the range of SIRs was
0.43–2.15, and all confidence intervals were overlapping
(Fig. 10) [12, 14, 16, 17, 20–22, 24–28, 36]. In three
studies, authors reported a significant decrease in risk
compared with the RA population [12, 16, 36]. The total
pooled SIR for cervical cancer was 0.87 (0.72–1.05). For
prostate cancer, SIRs were reported in a total of 15
studies (8 from Smitten et al. [20–22, 24, 25, 27, 28, 36]
and 7 new [10, 12–17]). Overall, the range of SIRs was
0.35–3.20, and the total pooled SIR was 1.15 (0.98–1.34)
(Fig. 11) [10, 12–17, 20–22, 24, 25, 27, 28, 36].
Discussion
Although individual studies can show considerable vari-
ation, the results of this updated meta-analysis of the
incidence of malignancy in adult patients with RA are
generally consistent with previously reported data for all
specific malignancies [6]. The updated data reported here






















arthritis (RA) compared with the general population. CI, confidence
nancies; N, population size; SIR, standardized incidence ratio. *SIRs by
0.1 50.01.0
Source n/N SIR (95% CI)
Matteson 1991 (DMARDs) [32] 6/530 3.37 (1.58, 7.34)
McKendry 1993 (MTX) [37] 4/144 12.4 (3.38, 31.84)
Gridley 1993 [24] 68/11,683 1.31 (1.0, 1.7)
Moritomo 1995 [26] 0/655 0 (0, 1.82)
Kauppi 1996 [38] 73/8920 1.8 (1.4, 2.2)
Mellemkjaer 1996 [25] 308/20,699 1.5 (1.3, 1.7)
Cibere 1997 [22] 16/862 1.08 (0.61, 1.75)
Thomas 2000 [27] 472/26,623 1.39 (1.3, 1.5)
Askling 2005 [21] 330/53,067 1.48 (1.33, 1.65)
Askling 2005 (early RA) [21] 23/3703 2.4 (1.5, 3.6)
Askling 2005 (anti-TNF) [21] 10/4160 1.8 (0.9, 3.3)
Setoguchi 2006 [36] 169/7830 1.8 (1.52, 2.05)
Abasolo 2007 [20] 7/789 3.5 (1.4, 7.1)
Wolfe 2007 [28] 112/13,869 1.2 (1.0, 1.4)
Buchbinder 2008 [19] 14/458 2.9 (1.6, 4.8)
Hemminki 2008 [14] 448/42,262 1.73 (1.57, 1.89)
Parikh-Patel 2009 [16] 1178/84,475
Female* 1.28 (1.19, 1.38)
Male* 1.65 (1.49, 1.81)
Hellgren 2010† [10] 34/6745 2.24 (1.49, 3.36)
Chen 2011 [12] 123/23,644 1.36 (1.34, 1.38)
Yamada 2011 [17] 34/7566 2.29 (1.57, 3.21)
Female* 1.66 (0.89, 2.85)
Male* 3.02 (1.85, 4.67)
Dreyer 2013 [13] 20/3812 1.67 (1.08, 2.59)
Mercer 2013 [15] 46/3771 2.39 (1.75, 3.19)
Female* 2.66 (1.79, 3.80)
Male* 2.01 (1.15, 2.36)
Total pooled SIR   23 1.64 (1.51, 1.79)
New studies
Fig. 6 Relative risk of lung cancer in patients with rheumatoid arthritis (RA) compared with the general population. CI, confidence interval;
DMARD, disease-modifying antirheumatic drug; MTX, methotrexate; n, number of malignancies; N, population size; SIR, standardized incidence
ratio; TNF, tumor necrosis factor. *SIRs by sex are included in total pooled SIR only if overall SIR was not available. †Reported as odds ratio
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cancer and lymphoma when compared with the general
population. Lymphoma was associated with the greatest
relative risk, especially Hodgkin disease, with a 12-fold in-
crease reported in one study [15] and an increase in
women versus men in another [16]. Lung cancer generally
showed a twofold increase in risk [10, 12–17, 19]. AsFig. 7 Relative risk of colorectal cancer in patients with rheumatoid arthritis (R
DMARD, disease-modifying antirheumatic drug; n, number of malignancies; N
factor. *SIRs by sex are included in total pooled SIR only if overall SIR was notpreviously noted, a decreased risk overall of colorectal
cancer in patients with RA compared with the general
population was found. For melanoma, the pooled SIR was
significantly greater than unity, although few of the indi-
vidual point estimates were statistically significant. Breast
and cervical cancers in general showed a decrease in risk
overall that failed to reach statistical significance.A) compared with the general population. CI, confidence interval;
, population size; SIR, standardized incidence ratio; TNF, tumor necrosis
available. †Reported as odds ratio
Source n/N SIR (95% CI)
Gridley 1993 [24] 106/11,683 0.79 (0.6, 1.0)
Moritomo 1995 [26] 3/655 1.68 (0.34, 4.91)
Mellemkjaer 1996 [25] 186/20,699 0.8 (0.7, 0.9)
Cibere 1997 [22] 18/862 0.9 (0.46, 1.24)
Thomas 2000 [27] 249/26,623 0.95 (0.83, 1.07)
Askling 2005 [21] 471/53,067 0.83 (0.76, 0.91)
Askling 2005 (early RA) [21] 13/3703 0.6 (0.3, 1.0)
Askling 2005 (anti-TNF) [21] 8/4160 0.4 (0.2, 0.9)
Abasolo 2007 [20] 2/789 0.9 (0.1, 3.2)
Setoguchi 2006 (DMARDs) [36] 112/7830 0.9 (0.73, 1.06)
Wolfe 2007 [28] 102/13,869 0.8 (0.6, 0.9)
Buchbinder 2008 [19] 4/458 0.7 (0.2, 1.7)
Hemminki 2008 [14] 642/42,262 0.97 (0.90, 1.05)
Parikh-Patel 2009 [16] 842/84,475 0.63 (0.59, 0.67)
Hellgren 2010* [10] 42/6745 0.89 (0.64, 1.23)
Chen 2011 [12] 123/23,644 1.21 (1.19, 1.23)
Yamada 2011 [17] 20/7566 1.05 (0.64, 1.62)
Dreyer 2013 [13] 14/3812 0.89 (0.53, 1.51)
Mercer 2013 [15] 30/3771 1.07 (0.72, 1.52)
Total pooled SIR 19 0.86 (0.73, 1.01)
0.1 10.01.0
New studies
Fig. 8 Relative risk of breast cancer in patients with rheumatoid arthritis (RA) compared with the general population. CI, confidence interval;
DMARD, disease-modifying antirheumatic drug; n, number of malignancies; N, population size; SIR, standardized incidence ratio; TNF, tumor necrosis
factor. *Reported as odds ratio
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the risk of certain malignancies in patients with RA have
been proposed. It is thought that ongoing immunologic
stimulation over time may increase the risk of malignant
transformation of immune system cells and decrease the
number of T-suppressor lymphocytes, thus increasing
rates of lymphoma malignancy in patients with RA [4].
Chronic lung inflammation due to the disease in patients
with RA may explain the increased risk of lung cancer.
Smoking increases the risk of both RA and lung cancer;
however, the SIRs reported here were not adjusted for
smoking, so it is not possible to rule out the increase inAskling 2005 (anti-TNF) [21]
Source n/N
Gridley 1993 [24] 12/11,683
Female*
Male*
Moritomo 1995 [26] 1/655
Female*
Mellemkjaer 1996 [25] 37/20,699
Female*
Male*
Cibere 1997 [22] 45/862
Thomas 2000 [27] 28/26,623
Female*
Male*
Askling 2005 [21] 120/53,067
Askling 2005 (early RA) [21] 4/3703
1/4160
Setoguchi 2006 (DMARDs) [36] 29/7830
Abasolo 2007 [20] 1/789
Male*
Wolfe 2007 [28] 32/13,869
Buchbinder 2008 [19] 7/458
Hemminki 2008 [14] 143/42,262
Parikh-Patel 2009 [16] 184/84,475
Female*
Male*
Hellgren 2010† [10] 11/6745
Chen 2011 [12] 3/23,644
Yamada 2011 [17] 4/7566
Female*
Male*
Dreyer 2013 [13] 3/3812
Mercer 2013 [15] 9/3771
Female*
Total pooled SIR 21
0
New studies
Fig. 9 Relative risk of melanoma in patients with rheumatoid arthritis (RA) co
disease-modifying antirheumatic drug; n, number of malignancies; N, populat
*SIRs by sex are included in total pooled SIR only if overall SIR was not availabSIR being due to an indirect association. Thus, the risk
of both lymphoma and lung cancer has been hypothe-
sized to be dependent on the level of disease activity ex-
perienced by the patient [4, 6].
Patients with RA continued to show no increase in
overall risk of colorectal and breast cancers, in contrast
to their increased risk for lung cancer and lymphoma. In
patients with RA, any observed decreased risk in colo-
rectal malignancy may be due to the increased use of
non-steroidal anti-inflammatory drugs, which are known
to decrease this risk [4, 6]. Overall, the risk of malig-

































mpared with the general population. CI, confidence interval; DMARD,
ion size; SIR, standardized incidence ratio; TNF, tumor necrosis factor.
le. †Reported as odds ratio
Source n/N SIR (95% CI)
Gridley 1993 [24] 17/11,683 0.9 (0.5, 1.4)
Moritomo 1995 [26] 3/655 2.15 (0.43, 6.27)
Mellemkjaer 1996 [25] 40/20,699 1.1 (0.8, 1.5)
Cibere 1997 [22] 1/862 0.49 (0.06, 2.76)
Thomas 2000 [27] 26/26,623 0.89 (0.58, 1.31)
Askling 2005 [21] 33/53,067 1.03 (0.71, 1.45)
Askling 2005 (early RA) [21] 1/3703 0.8 (0.02, 4.3)
Askling 2005 (anti-TNF) [21] 1/4160 1.0 (0.0, 5.8)
Setoguchi 2006 (DMARDs) [36] 16/7830 0.5 (0.31, 0.82)
Abasolo 2007 [20] 1/789 1.0 (0.1, 22.7)
Wolfe 2007 [28] 4/13,869 0.8 (0.4, 1.9)
Hemminki 2008 [14] 58/42,262 1.26 (0.95, 1.62)
Parikh-Patel 2009 [16] 47/84,475 0.43 (0.31, 0.57)
Chen 2011 [12] 45/23,644 0.86 (0.84, 0.89)
Yamada 2011 [17] 4/7566 1.36 (0.37, 3.49)
Total pooled SIR 15 0.87 (0.72, 1.05)
0 30.0  1.0 
New studies
Fig. 10 Relative risk of cervical cancer in patients with rheumatoid arthritis (RA) compared with the general population. CI, confidence interval;
DMARD, disease-modifying antirheumatic drug; n, number of malignancies; N, population size; SIR, standardized incidence ratio; TNF, tumor
necrosis factor
Simon et al. Arthritis Research & Therapy  (2015) 17:212 Page 8 of 10the autoimmune pathogenesis of RA and common
etiology between RA and malignancy, including genetic
factors, smoking-related tissue necrosis and viral infec-
tion [9]. The three other site-specific malignancies ex-
amined here but not studied previously by Smitten et al.
[6]—prostate cancer, cervical cancer and melanoma—are
all common cancers, with cervical cancer being attribut-
able to viral infection. In the present analysis, there did
not appear to be a consistent trend of increased or de-
creased risk of prostate cancer, cervical cancer or melan-
oma among patients with RA compared with the general
population. One review published in 2008 that did not
meet our criteria showed melanoma results that were con-
sistent with our present assessment. Some populations
showed an increase in risk, whereas others did not [8].
This review, like that of Smitten et al. [6], is based on
observational, real-world clinical data; however, these in-
dividual studies may have potential limitations. Although
most of the individual estimates were derived from simi-
lar database studies, their study designs (including popu-
lations, data sources, follow-up times, data analysis andFig. 11 Relative risk of prostate cancer in patients with rheumatoid arthritis
n, number of malignancies; N, population size; SIR, standardized incidenceprocedures of reporting, particularly when linked to a
cancer registry) were a source of heterogeneity among
the studies and may be associated with bias of varying
magnitude. In addition, other potential sources of hetero-
geneity included geography and/or region, stage and se-
verity of RA, and treatment. Such heterogeneity should be
considered in any meta-analysis; the DerSimonian and
Laird technique used in this study [11] assumes hetero-
geneity across studies and incorporates it into the esti-
mation of the pooled SIRs and their confidence limits.
Therefore, although the variation observed among the in-
dividual SIRs reported should be treated with caution
when interpreting these data, it should be recognized that
this variation was accounted for in the analyses resulting
in the pooled SIRs.
For example, with regard to treatment, Dreyer et al. [13]
evaluated the effect of tumor necrosis factor (TNF) inhibi-
tor treatment on risk rate by examining the treated and
non-treated populations separately (only non-treated data
included in this analysis), whereas Mercer et al. [15]
evaluated biologic-naive patients. Buchbinder et al. [19](RA) compared with the general population. CI, confidence interval;
ratio. *Reported as odds ratio
Simon et al. Arthritis Research & Therapy  (2015) 17:212 Page 9 of 10examined malignancy risk only in patients with RA receiv-
ing methotrexate. However, the rest of the patients in
these studies are likely to have received treatments for
RA, therefore making it difficult to differentiate the effects
of treatment and disease. Nonetheless, to further under-
stand which malignancies may be related to treatment ver-
sus the underlying disease, it is important, where possible,
to quantify differences in malignancy rates between pa-
tients with RA treated with non-biologic DMARDs and
those treated with biologic DMARDs. Whether biologic
agents, predominantly TNF inhibitors, increase the risk of
malignancy has been debated [9]. Data have shown that
use of TNF inhibitors was not associated with a major
further increase in risk in the already elevated lymphoma
occurrence in patients with RA [39–44]. However, they do
appear to increase the risk of skin cancer, including
melanoma [39–43]. Furthermore, the data presented by
Simon et al. suggest that the observed incidence of total
malignancy and those for breast, colorectal and lung can-
cers and lymphoma in patients treated with abatacept was
largely consistent with that expected of patients with RA
treated with non-biologic DMARDs [45].
Conclusions
The additional data presented here are consistent with
previously reported data [6] for all specified malignancies.
For overall malignancy, the new studies analyzed here
show a similar increase in risk compared with that pre-
viously reported. In addition, patients with RA continue to
be at an increased risk of lung cancer and lymphoma when
compared with the general population. Further studies
examining specific aspects such as treatments, smoking or
other lifestyle factors are needed to investigate the under-
lying mechanisms for the increased or decreased risk of
specific cancers observed in patients with RA compared
with the general population. Also, it is important to quan-
tify any differences in malignancy risks between patients
with RA who are treated with non-biologic DMARDs and
those treated with biologic DMARDs, as understanding
which malignancies may be related to the treatment as
opposed to being related to underlying disease will allow
patients to be advised and monitored accordingly.
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